Abstract: The present invention is a method of treating or preventing Mycobacterium tuberculosis infection in a subject by administering to the subject an effective amount of oxazolidinone, specifically (N—(((S)-3-(dibenzo[b,e][1,4]dioxin-7-yl)-2-oxooxazolidin-5-yl)methyl)acetamide) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

Abstract: The present invention is a method of treating or preventing Mycobacterium tuberculosis infection in a subject by administering to the subject an effective amount of oxazolidinone, specifically(N-(((S)-3-(dibenzo[b,e][1,4]dioxin-7-yl)-2-oxooxazolidin-5-yl)methyl)acetamide) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

Abstract: The present invention is a method of treating or preventing Mycobacterium tuberculosis infection in a subject by administering to the subject an effective amount of oxazolidinone, specifically (N—(((S)-3-(dibenzo[b,e][1,4]dioxin-7-yl)-2-oxooxazolidin-5-yl)methyl)acetamide) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

Abstract: The present invention is a method of treating or preventing Mycobacterium tuberculosis infection in a subject by administering to the subject an effective amount of oxazolidinone, specifically (N—(((S)-3-(dibenzo[b,e][1,4]dioxin-7-yl)-2-oxooxazolidin-5-yl)methyl)acetamide) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

Abstract: The present invention is a method of treating or preventing Mycobacterium tuberculosis infection in a subject by administering to the subject an effective amount of oxazolidinone, specifically (N-(((S)-3-(dibenzo[b,e][1,4]dioxin-7-yl)-2-oxooxazolidin-5-yl)methyl)acetamide) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

Abstract: Disclosed are oxazolidinone compounds of Formula I: (I) salts thereof, antibacterial pharmaceutical compositions containing them, and use of the compounds to inhibit bacterial growth in mammals, including humans.

Abstract: The present invention is a method of treating or preventing Mycobacterium tuberculosis infection in a subject by administering to the subject an effective amount of oxazolidinone, specifically (N-(((S)-3-(dibenzo[b,e][1,4]dioxin-7-yl)-2-oxooxazolidin-5-yl)methyl)acetamide) or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof.

Abstract: Disclosed are oxazolidinone compounds of Formula I: (I) salts thereof, antibacterial pharmaceutical compositions containing them, and use of the compounds to inhibit bacterial growth in mammals, including humans.

Abstract: The present invention pertains, among other things, to polymers having one or more lipophilic hydrocarbon segments and one or more biodegradable polymeric segments, to methods of making such polymers and to products formed using such polymers.

Abstract: Nanoparticle precursor structures, nanoparticle structures, and composite materials that include the nanoparticle structures in a polymer to form a composite material. The nanoparticle structures have chemical linkage moieties capable of forming non-covalent bonds with portions of a polymer for the composite material. Such composite materials are useful as biomaterials in medical devices.

Abstract: Medical copolymers are provided which comprise (a) a polymer backbone comprising (i) a plurality of —C?C— groups within the polymer backbone, (ii) a plurality of —R9— groups within the polymer backbone, wherein R9 comprises a radical-substituted C2-C10 cyclic or heterocyclic group, or (iii) both a plurality of —C?C— groups and a plurality of —R9— groups within the polymer backbone, (b) a plurality of hydrocarbon-based pendant groups along the polymer backbone that comprise a saturated or unsaturated carbon chain of at least four carbons in length, and (c) a plurality of zwitterionic pendant groups along the polymer backbone that comprise a positively charged quaternary ammonium group and a negatively charged phosphate group. Methods of forming such copolymers, medical products that contain such copolymers, and methods of making such medical products are also disclosed.

Abstract: A method of synthesizing a crystalline molecular sieve having an MSE framework type comprises crystallizing a reaction mixture comprising a source of water, a source of an oxide of a tetravalent element, Y, selected from at least one of silicon, tin, titanium, vanadium and germanium, a source of an alkali or alkaline earth metal, M, and a source of organic cations, Q, having the following general structure: in which R1 is hydrogen or an alkyl group, and R2 and R3 are alkyl groups.

Abstract: The present invention pertains, among other things, to polymers having one or more lipophilic hydrocarbon segments and one or more biodegradable polymeric segments, to methods of making such polymers and to products formed using such polymers.

Abstract: Nanoparticle precursor structures, nanoparticle structures, and composite materials that include the nanoparticle structures in a polymer to form a composite material. The nanoparticle structures have chemical linkage moieties capable of forming non-covalent bonds with portions of a polymer for the composite material. Such composite materials are useful as biomaterials in medical devices.

Abstract: Various aspects of the invention relate to implantable medical devices, which comprise a layer of material (e.g., in the form of a sheet, tube, etc.) that comprises a bioerodible polymer and a therapeutic agent. Other aspects of the invention relate to methods of forming such devices. Still other aspects of the invention relate to methods of treatment using such devices.

Abstract: Nanoparticle precursor structures, nanoparticle structures, and composite materials that include the nanoparticle structures in a polymer to form a composite material. The nanoparticle structures have chemical linkage moieties capable of forming non-covalent bonds with portions of a polymer for the composite material. Such composite materials are useful as biomaterials in medical devices.

Abstract: According to an aspect of the present invention, medical copolymers are provided which comprise (a) a polymer backbone comprising (i) a plurality of —C?C— groups within the polymer backbone, (ii) a plurality of -R9- groups within the polymer backbone, wherein R9 comprises a radical-substituted C2-C10 cyclic or heterocyclic group, or (iii) both a plurality of —C?C— groups and a plurality of -R9- groups within the polymer backbone (b) a plurality of hydrocarbon-based pendant groups along the polymer backbone that comprise a saturated or unsaturated carbon chain of at least four carbons in length, and (c) a plurality of zwitterionic pendant groups along the polymer backbone that comprise a positively charged quaternary ammonium group and a negatively charged phosphate group. Further aspects of the invention, among others, relate to methods of forming such copolymers, medical products that contain such copolymers, and methods of making such medical products.

Abstract: A method of synthesizing a crystalline molecular sieve having an MSE framework type comprises crystallizing a reaction mixture comprising a source of water, a source of an oxide of a tetravalent element, Y, selected from at least one of silicon, tin, titanium, vanadium and germanium, a source of an alkali or alkaline earth metal, M, and a source of organic cations, Q, having the following general structure: in which R1 is hydrogen or an alkyl group, and R2 and R3 are alkyl groups.

Abstract: Nanoparticle precursor structures, nanoparticle structures, and composite materials that include the nanoparticle structures in a polymer to form a composite material. The nanoparticle structures have chemical linkage moieties capable of forming non-covalent bonds with portions of a polymer for the composite material. Such composite materials are useful as biomaterials in medical devices.

Abstract: Nanoparticle precursor structures, nanoparticle structures, and composite materials that include the nanoparticle structures in a polymer to form a composite material. The nanoparticle structures have chemical linkage moieties capable of forming non-covalent bonds with portions of a polymer for the composite material. Such composite materials are useful as biomaterials in medical devices.